Last reviewed · How we verify
Zibotentan/Dapagliflozin
Zibotentan/Dapagliflozin is a combination of a selective endothelin receptor antagonist and a sodium-glucose cotransporter 2 inhibitor.
Zibotentan/Dapagliflozin is a combination of a selective endothelin receptor antagonist and a sodium-glucose cotransporter 2 inhibitor. Used for Chronic heart failure.
At a glance
| Generic name | Zibotentan/Dapagliflozin |
|---|---|
| Sponsor | AstraZeneca |
| Drug class | SGLT2 inhibitor |
| Target | SGLT2 |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | Phase 3 |
Mechanism of action
Zibotentan works by blocking the action of endothelin-1, a peptide that causes blood vessels to constrict. Dapagliflozin, on the other hand, inhibits the sodium-glucose cotransporter 2, reducing glucose reabsorption in the kidneys and promoting glucose excretion in the urine.
Approved indications
- Chronic heart failure
Common side effects
- Increased risk of diabetic ketoacidosis
- Hypotension
- Hyperkalemia
Key clinical trials
- Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Participants With Chronic Kidney Disease and High Proteinuria (ZENITH High Proteinuria) (PHASE3)
- A Study to Investigate the Concentrations of Zibotentan and Dapagliflozin in Blood When Given With and Without Food (PHASE1)
- A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK (PHASE2)
- A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria (PHASE2)
- Zibotentan and Dapagliflozin Combination, EvAluated in Liver Cirrhosis (ZEAL Study) (PHASE2)
- Zibotentan and Dapagliflozin in Patients With Type 2 Diabetes and Elevated Albuminuria (PHASE2)
- Zibotentan and Dapagliflozin for the Treatment of CKD (ZENITH-CKD Trial) (PHASE2)
- Study to Collect Samples for MIST Analysis of Zibotentan and Bioavailability of Zibotentan and Dapagliflozin in Heatlhy Participants (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zibotentan/Dapagliflozin CI brief — competitive landscape report
- Zibotentan/Dapagliflozin updates RSS · CI watch RSS
- AstraZeneca portfolio CI